GSA Capital Partners LLP acquired a new position in Haemonetics Co. (NYSE:HAE) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,263 shares of the medical instruments supplier’s stock, valued at approximately $285,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Toronto Dominion Bank acquired a new stake in Haemonetics in the second quarter worth approximately $27,000. CSat Investment Advisory L.P. raised its stake in shares of Haemonetics by 187.5% in the 2nd quarter. CSat Investment Advisory L.P. now owns 322 shares of the medical instruments supplier’s stock worth $29,000 after buying an additional 210 shares in the last quarter. Assetmark Inc. lifted its holdings in shares of Haemonetics by 4,275.0% in the second quarter. Assetmark Inc. now owns 350 shares of the medical instruments supplier’s stock valued at $31,000 after buying an additional 342 shares during the period. Private Capital Group LLC boosted its stake in Haemonetics by 62.5% during the second quarter. Private Capital Group LLC now owns 559 shares of the medical instruments supplier’s stock valued at $50,000 after buying an additional 215 shares in the last quarter. Finally, Tompkins Financial Corp acquired a new position in Haemonetics during the second quarter worth about $50,000. Hedge funds and other institutional investors own 96.33% of the company’s stock.

Several equities analysts have recently weighed in on HAE shares. Barrington Research upgraded shares of Haemonetics from a “market perform” rating to an “outperform” rating and set a $106.00 price objective for the company in a research report on Thursday, November 5th. Needham & Company LLC restated a “buy” rating and issued a $119.00 price target on shares of Haemonetics in a research report on Tuesday, August 4th. Raymond James upped their price target on Haemonetics from $100.00 to $130.00 and gave the company an “outperform” rating in a report on Monday, November 2nd. TheStreet raised Haemonetics from a “c+” rating to a “b” rating in a research note on Wednesday, November 4th. Finally, Zacks Investment Research raised Haemonetics from a “strong sell” rating to a “hold” rating and set a $98.00 target price on the stock in a research report on Tuesday, October 6th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $112.60.

In other Haemonetics news, CFO William P. Mr. Burke sold 1,161 shares of Haemonetics stock in a transaction dated Monday, October 26th. The stock was sold at an average price of $106.00, for a total transaction of $123,066.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders have sold a total of 1,543 shares of company stock valued at $161,917 over the last 90 days. Corporate insiders own 1.63% of the company’s stock.

NYSE HAE opened at $115.76 on Friday. The firm’s 50 day moving average price is $100.16 and its two-hundred day moving average price is $93.84. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.14 and a current ratio of 2.25. Haemonetics Co. has a twelve month low of $63.41 and a twelve month high of $126.74. The stock has a market cap of $5.88 billion, a price-to-earnings ratio of 55.92, a PEG ratio of 3.96 and a beta of 0.52.

Haemonetics (NYSE:HAE) last issued its earnings results on Wednesday, November 4th. The medical instruments supplier reported $0.62 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.51 by $0.11. The business had revenue of $209.50 million during the quarter, compared to analysts’ expectations of $207.66 million. Haemonetics had a return on equity of 22.85% and a net margin of 11.76%. Haemonetics’s revenue was down 17.2% compared to the same quarter last year. During the same quarter last year, the firm posted $0.72 earnings per share. On average, research analysts forecast that Haemonetics Co. will post 2.42 EPS for the current fiscal year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Further Reading: What is the Coverage Ratio?

Want to see what other hedge funds are holding HAE? Visit to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with's FREE daily email newsletter.